Clinical Trial Update: Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating AT-101 in combination with Rituximab for previously untreated grade 1-2 follicular lymphoma, focusing on safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• AT-101 (gossypol acetic acid)
• Rituximab (rituximab)

Snippet

Sponsor: Ascenta Therapeutics | Conditions: Follicular Lymphoma | Phase 2 | Status: COMPLETED